Business
Immunome Announces Initiation of Phase 1b Study of IMM-BCP-01 for the Treatment of COVID-19
First study subject has been dosed in a single dose/dose escalation study of recently diagnosed COVID-19 patients Study will evaluate safety as the primary
About this update from Immunome, Inc.
[{"type":"text","content":"\n\nFirst study subject has been dosed in a single dose/dose escalation study of recently diagnosed COVID-19 patients\n\n\nStudy will evaluate safety as the primary end point with pharmacokinetics (PK) and virology as secondary assessments\n\n\n EXTON, Pa.--(BUSINESS WIRE)--\nImmunome, Inc. (Nasdaq: IMNM), a biopharmaceutical company that utilizes its human memory B cell platform to discover and develop first-in-class antibody therapeutics, today announced the first patient has been enrolled in a clinical trial of IMM-BCP-01, a three-antibody cocktail for the treatment of SARS-CoV-2 (COVID-19). Topline data is expected in the second half of this year, which is an update from our prior guidance.\n\nThe Phase 1b study of IMM-BCP-01 is a single dose, dose escalation study in recently diagnosed COVID-19 patients. The primary study endpoint is safety, with pharmacokinetics (PK) and virology as secondary assessments. IMM-BCP-01 is designed to target three distinct, non-overlapping epitopes of SARS-CoV-2, to neutralize the virus and initiate multiple viral clearance mechanisms simultaneously, including complement fixation and phagocytosis.\n\nPreviously announced data has shown that IMM-BCP-01 is effective in vitro against live virus versions of the SARS-CoV-2 Omicron variant (BA.1 and BA.2).\n\n“We are pleased that we have begun studying IMM-BCP-01 in patients with COVID-19,” said Purnanand Sarma, PhD, President & CEO of Immunome. “Based on the encouraging preclinical research, including data showing that our antibody cocktail demonstrated effectiveness against the Omicron variants BA.1 and BA.2 in live virus testing and Omicron BA.1 in-vivo in hamsters, we believe that IMM-BCP-01 can play an important role in addressing COVID-19.”\n\nThe investigational work for IMM-BCP-01 was funded by the U.S. Department of Defense’s (DOD) Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND) in collaboration with the Defense Health Agency (DHA) (Contract number: W911QY-20-9-0019).\n\nAbout IMM-BCP-01\n\nIMM-BCP-01 is a three-antibody cocktail targeting non-overlapping regions of the Spike protein of SARS-CoV-2, including highly conserved, subdominant epitopes, which elicits both ACE2 and non-ACE2 dependent neutralization, and induces natural viral clearance mechanisms, such as antibody dependent cel...